Ellen (55 years old) has been diagnosed with breast cancer. It is her second time with active cancer, and she has got metastasis in pelvic. Among other drugs she is treated with capecitabine for her cancer. After starting capecitabine Ellen has developed problems feeling her feet and hands, diarrhea, nausea, vomiting and fatigue.

The fluoropyrimidines (capeitabine) are inactivated by hepatic dihydro-pyrimidine dehydrogenase (DPYD). A polymorphism in the fluoropyri-midine-metabolizing enzyme DPYD (Dihydropyrimidine Dehydrogenase ) is strongly associated with severe and life-threatening toxicity.

Most medications including cancer medication exhibit a wide inter-individual variability in their efficacy. A large part of this variability is due to inherited differences in genes. Some of these changes can be found using a pharmacogenomic test as you can see in the study below.

The Personal Medicine Profile is exactly such a pharmacogenomic test and can be used as a Decision Support Tool for Healthcare Personnel and patients to help them predict which medical treatment will benefit the patient -> helping to find the right medication, in the right dose to the right patient.

The right diagnosis is still to be made by the Doctor. Please, do not change any medication without consulting a Doctor.

Personal Medicine Profile™

  • An advanced drug response test covering more than 200 of the most frequent prescriptions within heart, pain, rheumatism, gastroenterology, mental health, multiple diseases, cancer and lifestyle

  • Free updates of your report for new medication information and dosage recommendations

  • You have access to your result day and night -> share it with your doctor or pharmacy

  • Several insurance companies help cover the cost

Order Now

PMP is a once only investment. Use it when new medicine is prescribed.

We take good care of your personal data according to GDPR (EU) with our Security by Design set-up.

Read more about: GDPRPrivacy policyData SafetyQuality Policy

A study from Netherlands investigated the feasibility, safety and cost using DPYD genotyped-guided dosing based on pharmacogenomic test on 2.038 patients

The variant allele-carrier was shown to be strongly associated with fluoropyrimidine-induced severe and life-threatening toxicity.
Today, the European Medicine Agency (EMA) recommends a genetic test when using Fluoropyrimidines.

Source: Deenen MU et al. Upfront genotyping of DPYD*2A to individualize fluoropyrimidine therapy: a safety and cost analysis: J. Clin. Oncol. 2016; 34(3) 227-34

Four simple and easy steps

Personal Medicine Profile

We are all different

The practice of medicine has always been about treating each person as an individual patient. For a long time, clinicians have observed that patients with the same diagnosis may respond differently to the same medical treatment.

Advances in technology have made it possible to identify genetic variations determining the effectiveness of commonly prescribed medications.

Personal Medicine Profile relies on this very technology.

We Protect Your Privacy

We promise to keep your personal and genetic information confidential. Here’s what we do:

Your biological sample is destroyed after quality control. We do not sell it or hand it over to third parties.

Throughout our processes we handle your sample anonymously. Only authorized personnel have access to your sample.

You have full access to your data and you can choose to share it with your Doctor or Pharmacy

We build our system based on “security by design” to protect your data from harm

Trusted Partners

Genetelligence focus on services, research and development in the field of personalized medicine. Therefore, we work with a wide range of private and public institutions. Please, feel free to contact us for possible cooperation.